STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRX
  4. [Form 4] Marex Group plc Insider Trading Activity

Marex Group plc (MRX) president sells 13,264 shares in planned trades

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Marex Group plc President Simon Van Den Born reported open-market sales of a total of 13,264 ordinary shares. The trades occurred in two blocks at weighted average prices of $43.2683 and $43.9697 per share, executed under a pre-arranged Rule 10b5-1 plan entered into on December 12, 2025.

Following these transactions, he directly owns 1,522,229 ordinary shares, which include 383,741 shares underlying deferred bonus plan awards that may convert into ordinary shares upon vesting and settlement.

Positive

  • None.

Negative

  • None.
Insider Van Den Born Simon
Role President
Sold 13,264 shs ($577K)
Type Security Shares Price Value
Sale Ordinary Shares 8,710 $43.2683 $377K
Sale Ordinary Shares 4,554 $43.9697 $200K
Holdings After Transaction: Ordinary Shares — 1,526,783 shares (Direct)
Footnotes (1)
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on December 12, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $42.77 to $43.7650 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $43.77 to $44.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The number of ordinary shares reported herein includes 383,741 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.
Shares sold (first transaction) 8,710 shares Open-market sale of ordinary shares at $43.2683
Price (first transaction) $43.2683 per share Weighted average sale price on ordinary shares
Shares sold (second transaction) 4,554 shares Open-market sale of ordinary shares at $43.9697
Price (second transaction) $43.9697 per share Weighted average sale price on ordinary shares
Total shares sold 13,264 shares Combined open-market sales on April 1, 2026
Shares held after transactions 1,522,229 shares Direct ownership of Marex ordinary shares after sales
Deferred bonus plan awards 383,741 shares Ordinary shares underlying deferred bonus awards
Rule 10b5-1 plan financial
"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $42.77 to $43.7650 inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
deferred bonus plan awards financial
"The number of ordinary shares reported herein includes 383,741 shares underlying deferred bonus plan awards previously granted to the Reporting Person."
Deferred bonus plan awards are payments promised to employees or executives that are earned now but paid out later, often only if certain performance goals are met or the employee remains with the company. For investors, they matter because they influence management’s incentives and company expenses over time—like a delayed paycheck that encourages someone to stay and meet targets—and can affect future cash needs, reported compensation costs, and potential share dilution.
contingent right financial
"Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Van Den Born Simon
(Last)(First)(Middle)
C/O MAREX GROUP PLC, 155 BISHOPSGATE
(Street)
LONDONUNITED KINGDOMEC2M 3TQ
(City)(State)(Zip)
UNITED KINGDOM
(Country)		2. Issuer Name and Ticker or Trading Symbol
Marex Group plc [ MRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares04/01/2026S(1)8,710D$43.2683(2)1,526,783D
Ordinary Shares04/01/2026S(1)4,554D$43.9697(3)1,522,229(4)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on December 12, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $42.77 to $43.7650 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $43.77 to $44.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The number of ordinary shares reported herein includes 383,741 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.
/s/ Scott Linsley as Attorney-in-Fact, for Simon van den Born04/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Marex Group plc (MRX) report for Simon Van Den Born?

Marex Group plc’s president Simon Van Den Born reported selling 13,264 ordinary shares in open-market trades. The sales were split into two transactions and were executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025.

How many Marex Group plc (MRX) shares did the president sell and at what prices?

Simon Van Den Born sold 8,710 ordinary shares at a weighted average price of $43.2683 and 4,554 shares at $43.9697. Both transactions were reported as open-market sales of Marex Group plc ordinary shares.

How many Marex Group plc (MRX) shares does the president hold after the reported sales?

After the reported sales, Simon Van Den Born directly holds 1,522,229 ordinary shares of Marex Group plc. This figure includes shares already owned as well as those underlying certain deferred bonus plan awards granted to him.

Were the Marex Group plc (MRX) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan that Simon Van Den Born entered into on December 12, 2025. Such plans pre-schedule trades and can indicate routine portfolio management activity.

What are the deferred bonus plan awards mentioned in the Marex Group plc (MRX) Form 4?

The Form 4 notes that 383,741 of Simon Van Den Born’s reported ordinary shares relate to deferred bonus plan awards. Each award represents a contingent right to receive one ordinary share upon vesting and settlement, increasing his potential equity exposure.